Michael Artinger, PhD – Chief Executive Officer and Board Member. 

The focus of Dr. Artinger’s career has been transforming innovation into commercial opportunity. He has worked closely with universities and inventors across the nation to recognize the potential of their discoveries and has deep expertise across multiple operational roles and domains.

Dr. Artinger has over 23 years of operational experience in the life science industry and as been involved in the preclinical and clinical development of therapeutics and vaccines across multiple therapeutic areas. He has held appointments as Visiting Scientist in Medicine at both Harvard Medical School and Brigham and Women’s Hospital, and conducted his Postdoctoral research at the Cardiovascular Research Center at Massachusetts General Hospital and Harvard Medical School.

Dr. Artinger earned his Doctorate degree in Biology focusing on Developmental and Cell Biology, as well as his Baccalaureate degree in Applied Ecology from the University of California at Irvine.

Ulli Bayer, PhD – Chief Scientific Officer and Board Member.

In addition to his role with Neurexis, Dr. Bayer is a Professor in the Department of Pharmacology at the University of Colorado – Anschutz Medical Campus.

Dr. Bayer is the inventor of the tatCN19o peptide. His research interests include: Elucidating the molecular mechanisms underlying learning, memory and cognition; Applying fundamental neuroscience findings to better understand neurological disorders such as Alzheimer’s disease, Down syndrome, schizophrenia and addiction; Pursuing advances in neuroprotection after acute injuries such as stroke and global cerebral ischemia.

He conducted his Postdoctoral Fellowship in Neuroscience, Biochemistry and Cell Biology at Stanford University School of Medicine and earned his PhD in Molecular Biology from the Heinrich Pette Institute, Hamburg University.

Robyn Goforth, PhD – Vice President of Research and Development.

Dr. Goforth has over 15 years of experience in functional protein design and protein production. She has published over a dozen scientific papers in the fields of biochemistry and bioengineering. She has also been principal investigator and co-principal investigator on over $10MM in National Institute of Health, Department of Energy, and Small Business Innovation Research grants. 

She has extensive experience in drug development across multiple indications for both peptide and protein therapeutics. Her expertise is focused on the transition of potential high-value therapeutics from academic labs to privately funded small businesses. Dr. Goforth has more than a decade of experience leading R&D efforts that have been necessary to develop manufacturing platforms, complete FDA required pre-clinical studies, and raise the extensive investment required to fund drug development programs to the clinic.

Philip Chu, PhD – Director of Research and Development.

Dr. Chu is a neurobiologist by training with over 10 years of experience conducting fundamental and translational research. He has published 7 peer reviewed scientific papers in the areas of neuronal circuit physiology, cortical development, and neurological diseases. He has also supported early stage drug development programs through market research, due diligence assessments, and deep dive tactical research for a product development plan.

Dr. Chu received his Ph.D. from the Graduate Center of the City University of New York and completed a Postdoctoral Fellowship in the Department of Neurogenetics at the Weill Cornell Medical College. Prior to joining Neurexis, he served as research faculty at the University of Colorado, Anschutz Medical Campus in the department of Neurosurgery.